Welcome to our dedicated page for Vaxcyte SEC filings (Ticker: PCVX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vaxcyte, Inc. filings document a clinical-stage vaccine company developing bacterial-disease vaccine candidates and raising capital through registered common stock transactions. Recent Form 8-K reports cover financial results, business updates tied to VAX-31 and other pipeline programs, an underwritten common stock offering, an at-the-market sales agreement under an effective Form S-3 shelf registration, and a manufacturing services agreement for drug product supply.
Proxy materials disclose shareholder voting matters, board and governance information, executive compensation, and equity-plan matters. The filing record also identifies Vaxcyte’s Nasdaq-listed common stock under PCVX and formalizes material agreements, financing arrangements, and corporate disclosures related to its vaccine development and manufacturing strategy.
Andrew Guggenhime, listed as President and CFO of Vaxcyte, Inc. (PCVX) and a director, reported multiple dispositions of common stock tied to the vesting of restricted stock units (RSUs). On 09/02/2025 he surrendered 1,270, 2,381, and 1,429 shares to the issuer to cover tax withholding at a price of $31.56 per share. After those transactions his reported beneficial ownership in the class was 131,009, 128,628, and 127,199 shares on the separate reported lines. The filing notes that the total includes 329 shares acquired under the company Employee Stock Purchase Plan on May 16, 2025. The transactions appear to be routine tax-withholding actions related to RSU vesting.
Grant Pickering, who is listed as Vaxcyte, Inc.'s Chief Executive Officer and a director, reported transactions dated 09/02/2025 on Form 4. The filing shows three dispositions of Common Stock executed to satisfy tax withholding upon RSU vesting: 2,857 shares, 4,563 shares and 3,420 shares, each at a price of $31.56. Following those transactions the reported amounts beneficially owned on reported lines are 516,247, 511,684 and 508,264 shares respectively. The filing also reports 136,215 shares held indirectly in a trust for the reporting person’s son and 136,215 shares held indirectly in a trust for the reporting person’s daughter. The report notes 329 shares were acquired under the company ESPP on May 16, 2025. The Form 4 was signed by an attorney-in-fact on 09/04/2025.
Vaxcyte, Inc. (PCVX) Form 4: Elvia Cowan, SVP Finance, reported equity awards and purchases. On 08/29/2025 she was granted 2,810 restricted stock units (RSUs) that convert to common shares at vesting and a stock option covering 9,743 shares with an exercise price of $30.79 that vests monthly beginning 09/29/2025 and expires 08/29/2035. Following the reported RSU grant the filing shows she beneficially owns 27,205 shares, which includes 289 shares acquired under the Employee Stock Purchase Plan on 05/16/2025. All reported holdings are direct.
Janus Henderson Group plc filed a Schedule 13G/A reporting a sizable stake in Vaxcyte, Inc. The filing discloses an aggregate beneficial ownership reported as 14,691,344 shares (11.4% of the class). The document also states that an indirect subsidiary, JHIUS, may be deemed to beneficially own 14,554,724 shares (11.3% of the class), and that shared voting and shared dispositive power apply to those subsidiary-held shares.
The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, and it attaches a power of attorney authorizing two officers to make future ownership filings on the company’s behalf.
Q2 2025 highlights from Vaxcyte, Inc. (PCVX) 10-Q. The company reported consolidated total assets of $3,305,363 and a six-month net loss of $307,291 (YTD), including a Q2 net loss of $166,573. Cash and cash equivalents declined to $306,744 at June 30, 2025 from $387,878 at December 31, 2024. Short-term and long-term investments totaled $2,519,774 (fair value).
Operating results and cash flow: R&D expense rose to $194,179 in Q2 2025 (Q2 2024: $131,507) and G&A to $32,040 (Q2 2024: $21,474), driving total operating expenses of $226,219 for the quarter. Net loss per share was $(1.22) for Q2 and $(2.26) for the six months. Net cash used in operating activities was $287,440 for the six months.
- Shares outstanding: 129,816,472 at June 30, 2025.
- Manufacturing buildout: $196.3M capital expenditures (company-owned) and $94.3M facility buildout expenditures owned/controlled by Lonza (including CHF27M repurposing fee).
- Commitments: $484,543K non-cancelable purchase commitments to manufacturing partners; lease liabilities total $85,845K (discounted).